Shubhangi Shelke 
Highlights What Is Imlunestrant? Imlunstrant , marketed under the brand name Inlurio, is an oral selective estrogen receptor degrader (SERD) developed by Eli Lilly & Company. It is a next-generation endocrine therapy specifically designed for postmenopausal women and men with ER-positive, HER2-negative breast cancer that harbors ESR1 mutations. Unlike older SERDs that require injections, Imlunstrant …
Introduction The year 2025 marked a watershed moment in endocrinology with the FDA’s approval of Paltusotin (brand name: Palsonify) on September 25, 2025. This milestone marks the beginning of a once-daily oral therapy for adults with acromegaly who have had an inadequate response to surgery or for whom surgery is not an option. The Paltusotine …
Introduction Bladder cancer remains one of the most prevalent and recurring cancers in the world. While early-stage disease can often be treated successfully, certain patients face persistent recurrence despite conventional therapy. For adults with non-muscle invasive bladder cancer (NMIBC) that does not respond to Bacillus Calmette–Guérin (BCG), new hope has arrived in the form of …
Introduction When managing hereditary tyrosinemia type 1 (HT-1), a rare but serious metabolic disorder, Nitisinone has emerged as a life-saving therapy. This medication, developed in the 1990s, revolutionized treatment by preventing the buildup of toxic byproducts in the liver and kidneys. However, like every powerful drug, patients and caregivers must understand the Nitisinone side effects …
Introduction On July 2, 2025, the U.S. Food and Drug Administration (FDA) granted accelerated approval to linvoseltamab-gcpt (brand name: Lynozyfic) for the treatment of adults with relapsed or refractory multiple myeloma (R/R MM) who have received at least four prior lines of therapy. This linvoseltamab FDA approval represents a major milestone in oncology, especially for …
Introduction As we age, one of the most common eye diseases we encounter is presbyopia – the gradual loss of the eye’s ability to focus on near objects. It usually begins to affect people in their early to mid-40s and worsens with age. Reading glasses have long been a solution, but medical science is now …
Introduction On August 6, 2025, the U.S. Food and Drug Administration (FDA) granted accelerated approval to dordaviprone (brand name: Modeyso), making history as the first systemic therapy for patients with diffuse midline glioma (DMG) harboring the H3 K27M mutation. This approval is a landmark moment, offering hope for children and adults battling this devastating and …
The rilzabrutinib FDA approval on August 29, 2025, introduced a groundbreaking therapy for patients struggling with immune thrombocytopenia (ITP) and other immune-mediated conditions. Marketed as Wayrilz, rilzabrutinib is a selective oral Bruton’s tyrosine kinase (BTK) inhibitor that brings new hope to patients who often face limited treatment options and chronic complications. This milestone approval is …
Introduction Hereditary angioedema (HAE) is a rare genetic disorder that causes recurrent swelling of various tissues, such as the face, limbs, abdomen, or airways. These attacks can be painful, disabling, and sometimes life-threatening (especially if the airways are involved). While conventional treatments have made great progress, many patients still face uncertainty and recurrent episodes. Enter …
Introduction The U.S. Food and Drug Administration (FDA) granted accelerated approval to Zongertinib (brand name Hernexeos) on August 8, 2025, marking a significant milestone in lung cancer treatment. Zongertinib is approved for adults with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors harbor HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations and …
